Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15218250 | 0.96 | CA12 (0.51) | CA12CA1CA9ALDH1A1MAPT | |
| SCHEMBL8069545 | 0.89 | CA12 (0.63) | CA12CA1CA9LMNASMN1; SMN2 | |
| SCHEMBL3445522 | 0.87 | CA12 (0.53) | CA12CA1CA9ALDH1A1HPGD | |
| SCHEMBL14323764 | 0.85 | ALDH1A1 (0.45) | CA12CA1CA9ALDH1A1MAPT | |
| SCHEMBL1034686 | 0.85 | ALDH1A1 (0.42) | CA12CA1CA9ALDH1A1MAPT | |
| SCHEMBL10346036 | 0.84 | CA12 (0.57) | CA12CA1CA9ALDH1A1LMNA | |
| SCHEMBL5638579 | 0.84 | CA12 (0.57) | CA12CA1CA9ALDH1A1MAPT | |
| SCHEMBL1332078 | 0.82 | CA12 (0.56) | CA12CA1CA9ALDH1A1MAPT | |
| SCHEMBL13639225 | 0.82 | CA12 (0.56) | CA12CA1CA9LMNASMN1; SMN2 | |
| SCHEMBL8780766 | 0.82 | CA12 (0.56) | CA12CA1CA9ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691850-B2 | Substituted phenylaminothiazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| US-8691850-B2 | Substituted phenylaminothiazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-1812430-B1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1994031-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | Bayer HealthCare AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| EP-1812430-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006027142-A1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | CA12 4730/4885CA1 4551/4885CA9 4045/4885 |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | CA12 4861/4885CA1 4873/4885CA9 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.